Patents Assigned to Ludwig-Maximilians-Universitat
-
Patent number: 11958880Abstract: The present invention provides means and methods for equipping a polypeptide of interest at its C-terminus with a versatile adaptor amino acid that allows the functionalization of the polypeptide of interest.Type: GrantFiled: June 29, 2022Date of Patent: April 16, 2024Assignees: LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN, FORSCHUNGSVERBUND BERLIN E.V.Inventors: Heinrich Leonhardt, Jonas Helma, Dominik Schumacher, Christian Hackenberger
-
Patent number: 11827678Abstract: The present invention relates to a polypeptide comprising a silk polypeptide and an antigen. Further, the present invention relates to an article comprising the polypeptide. Furthermore, the present invention relates to a pharmaceutical composition comprising the article. In addition, the present invention relates to the article or pharmaceutical composition for use as a pharmaceutical, for inducing an immune response and/or for use in a prophylactic and/or therapeutic treatment of a disease.Type: GrantFiled: July 23, 2021Date of Patent: November 28, 2023Assignees: Amsilk GmbH, Ludwig-Maximilians-Universitat Munchen, Universitat BayreuthInventors: Lin Romer, Ute Slotta, Julia Engert, Gerhard Winter, Matthias Lucke, Thomas Scheibel
-
Patent number: 11746124Abstract: Disclosed are novel conjugates and processes for the preparation thereof.Type: GrantFiled: August 30, 2021Date of Patent: September 5, 2023Assignees: FORSCHUNGSVERBUND BERLIN E.V., LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHENInventors: Christian Hackenberger, Marc André Kasper, Maria Glanz, Tom Sauer, Dominik Schumacher, Jonas Helma-Smets, Heinrich Leonhardt, Andreas Stengl
-
Patent number: 11723922Abstract: The present invention relates to CXCR6-transduced (a) T cell(s) such as (a) CD8+ T cell(s), (a) CD4+ T cell(s), (a) CD3+ T cell(s), (a) ?? T cell(s) or (a) natural killer (NK) T cell(s) for targeted tumor therapy, nucleic acid sequences, vectors capable of transducing such (a) T cell(s), (a) transduced T cell(s) carrying the nucleic acid sequences or vectors of the present invention, methods and kits comprising the nucleic acid sequences or vectors of the present invention. The invention also provides the use of said transduced T cell(s) in a method for the treatment of diseases characterized by CXCL16 overexpression as well as a pharmaceutical composition/medicament comprising (a) transduced T cell(s) expressing the CXCR6 for use in methods of treating diseases characterized by CXCL16 overexpression.Type: GrantFiled: October 14, 2016Date of Patent: August 15, 2023Assignee: LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHENInventors: Sebastian Kobold, Stefan Endres, Moritz Rapp, Simon Grassmann
-
Patent number: 11667683Abstract: The present invention relates to a polypeptide comprising a silk polypeptide and an antigen. Further, the present invention relates to an article comprising the polypeptide. Furthermore, the present invention relates to a pharmaceutical composition comprising the article. In addition, the present invention relates to the article or pharmaceutical composition for use as a pharmaceutical, for inducing an immune response and/or for use in a prophylactic and/or therapeutic treatment of a disease.Type: GrantFiled: April 30, 2021Date of Patent: June 6, 2023Assignees: Amsilk GmbH, Ludwig-Maximilians-Universitat Munchen, Universitat BayreuthInventors: Lin Romer, Ute Slotta, Julia Engert, Gerhard Winter, Matthias Lucke, Thomas Scheibel
-
Patent number: 11513076Abstract: The present invention relates to a method and a DNA nanostructure for detecting a target structure. In particular, the present invention relates to a DNA nanostructure, which ensures a preferably linear dependence on the number of marker molecules and the measurement signal regardless of the physical arrangement of a plurality of such DNA nanostructures by virtue of the skilled selection of the shape of the DNA nanostructure and the placement of the marker molecules attached to it. The invention additionally relates to the use of said DNA nanostructures and other nanoreporters, preferably in combination with adapters which bind specifically to target molecules, in a method for quantifying a plurality of target molecules, preferably in a simultaneous manner, using a multiplex method.Type: GrantFiled: June 14, 2017Date of Patent: November 29, 2022Assignee: LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHENInventors: Heinrich Grabmayr, Johannes Benedikt Woehrstein
-
Publication number: 20220332737Abstract: The present invention relates to novel hydrolytically stable carbon-cyclic 5-aza-2-deoxycytidine and carbocyclic 5-aza-cytidine compounds and pro-drugs thereof as hypomethylating agents.Type: ApplicationFiled: June 5, 2019Publication date: October 20, 2022Applicant: Ludwig-Maximilians-Universität MünchenInventor: Thomas CARELL
-
Publication number: 20220296718Abstract: The present invention relates to excipients for stabilizing active agents, in particular peptides, polypeptides, nucleic acids, viruses, virus-like particles, proton pump inhibitors and antibiotics. The excipient reduces aggregate and/or particle formation in preparations comprising said agents. The excipient is a diamide of a dicarboxylic acid comprising at least one N—H amido group, at least one unsubstituted or substituted N-hydroxyethylamido group and/or at least one unsubstituted N-hydroxymethylamido group. In particular, the excipient is N,N,N?,N?-tetrakis-(2-hydroxyethyl) adipinic acid amide.Type: ApplicationFiled: July 10, 2020Publication date: September 22, 2022Applicants: Ludwig-Maximilians-Universität München, Danmarks Tekniske Universitet (DTU)Inventors: Gerhard WINTER, Andreas TOSSTORFF, Günther PETERS
-
Publication number: 20220265782Abstract: The present invention relates to compositions comprising a therapeutic protein with enhanced stability, which comprise a piperazine- or morpholine-containing zwitterionic buffering substance, such as HEPES, in particular when used out of the common pH range. The compositions of the invention are particularly useful for topical administration The present invention further relates to the use of said compositions for treating bacterial infections, e.g. bacterial infections caused by Staphylococcus aureus such as methicillin-resistant Staphylococcus aureus (MRSA). The present invention further relates to the use of said compositions for preventing or eliminating nasal bacterial colonization or bacterial colonization of the skin.Type: ApplicationFiled: July 16, 2020Publication date: August 25, 2022Applicants: LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN, HYPHARM GMBHInventors: Gerhard WINTER, Simon EISELE, Sonja MOLINARO, Wolfgang MUTTER
-
Patent number: 11422094Abstract: The analysis of data from fluorescence microscopy is disclosed, more especially fluorescence fluctuation microscopy, being a correlation analysis of fluctuation of the fluorescence intensity enabling quantitative and dynamic information capture. In particular the analysis is described of characteristics such as concentrations, mobility, interactions, stoichiometry, etc. of mixtures of particular that are fluorescently labeled with differently colored fluorophores having different excitation/emission spectra using fluctuation microscopy.Type: GrantFiled: January 11, 2019Date of Patent: August 23, 2022Assignees: Universiteit Hasselt, Ludwig-Maximilians-Universität MünchenInventors: Jelle Hendrix, Nick Smisdom, Don Lamb, Waldemar Schrimpf
-
Patent number: 11401298Abstract: The present invention provides means and methods for equipping a polypeptide of interest at its C-terminus with a versatile adaptor amino acid that allows the functionalization of the polypeptide of interest.Type: GrantFiled: August 14, 2020Date of Patent: August 2, 2022Assignees: LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN, FORSCHUNGSVERBUND BERLIN E.V.Inventors: Heinrich Leonhardt, Jonas Helma, Dominik Schumacher, Christian Hackenberger
-
Patent number: 11229700Abstract: The present invention relates to a novel molecule comprising three binding sites with specificity for a tumor cell, for an effector cell and for a checkpoint molecule, respectively. Moreover, the present invention relates to a pharmaceutical composition comprising such a molecule and to uses of such a molecule.Type: GrantFiled: November 9, 2016Date of Patent: January 25, 2022Assignee: LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHENInventors: Karl-Peter Hopfner, Marion Subklewe, Nadine Magauer, Nadja Fenn
-
Patent number: 11180518Abstract: The present invention relates to a compound represented by the formula (E) which is useful for treating or preventing melanoma.Type: GrantFiled: May 11, 2018Date of Patent: November 23, 2021Assignees: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHENInventors: Dorothea Becker, Thomas M. Jovin, Christian Griesinger, Andrei Leonov, Sergey Ryazanov, Armin Giese, Tiago F. Outeiro, Diana F. Lazaro, Michael P. Schön, Margarete Schön
-
Patent number: 11161873Abstract: Disclosed are novel conjugates and processes for the preparation thereof. A process tor the preparation of alkene- or alkyne-phosphonamidates comprises the steps of (I) reacting a compound of formula (III), with an azide of formula (IV), to prepare a compound of formula (V), reacting a compound of formula (V) with a thiol-containing molecule of formula (VI), resulting in a compound of formula (VII).Type: GrantFiled: September 1, 2017Date of Patent: November 2, 2021Assignees: FORSCHUNGSVERBUND BERLIN E.V., LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHENInventors: Christian Hackenberger, Marc André Kasper, Maria Glanz, Tom Sauer, Dominik Schumacher, Jonas Helma-Smets, Heinrich Leonhardt, Andreas Stengl
-
Patent number: 11104708Abstract: The present invention relates to a polypeptide comprising a silk polypeptide and an antigen. Further, the present invention relates to an article comprising the polypeptide. Furthermore, the present invention relates to a pharmaceutical composition comprising the article. In addition, the present invention relates to the article or pharmaceutical composition for use as a pharmaceutical, for inducing an immune response and/or for use in a prophylactic and/or therapeutic treatment of a disease.Type: GrantFiled: June 13, 2017Date of Patent: August 31, 2021Assignees: Amsilk GmbH, Ludwig-Maximilians-Universitat Munchen, Universitat BayreuthInventors: Lin Romer, Ute Slotta, Julia Engert, Gerhard Winter, Matthias Lucke, Thomas Scheibel
-
Patent number: 10941200Abstract: The present invention relates to a binding molecule having a binding site within the ectodomain of the triggering receptor expressed on myeloid cells 2 (TREM2), wherein the binding molecule inhibits TREM2 cleavage. Said binding molecule is particularly useful for treating and/or preventing a neurological disorder, such as a neurodegenerative disorder. Also encompassed by the present invention is a pharmaceutical composition for use in treating and/or preventing a neurological disorder, wherein the pharmaceutical composition comprises the binding molecule of the present invention. Neurodegenerative disorders that may be treated and/or prevented by using the binding molecule of the present invention include Alzheimer's disease (AD), Frontotemporal lobar degeneration (FTLD), FTLD-like syndrome, Parkinson's disease, Nasu-Hakola disease, Multiple sclerosis (MS), Huntington disease, immune-mediated neuropathies, or Amyotrophic lateral sclerosis (ALS).Type: GrantFiled: July 24, 2017Date of Patent: March 9, 2021Assignees: Deutsches Zentrum Für Neurodegenerative Erkrankungen EV, Ludwig-Maximilians-Universität MünchenInventors: Christian Haass, Gernot Kleinberger, Kai Schlepckow
-
Patent number: 10851411Abstract: The present invention relates to methods of determining the sequence of nucleotides in target nucleic acid molecules. Thus, the invention relates to methods of sub-unit sequencing. The methods comprise the use of identification nucleic acid detection entities which specifically hybridize to the target nucleic acid, bind identification tags and have localization tags transiently bind thereto.Type: GrantFiled: February 6, 2017Date of Patent: December 1, 2020Assignees: Ludwig-Maximilians-Universität München, XGenomes Corp.Inventors: Johannes B. Wöhrstein, Kalim Mir, Ralf Jungmann, Florian Schüder
-
Publication number: 20200348234Abstract: The analysis of data from fluorescence microscopy is disclosed, more especially fluorescence fluctuation microscopy, being a correlation analysis of fluctuation of the fluorescence intensity enabling quantitative and dynamic information capture. In particular the analysis is described of characteristics such as concentrations, mobility, interactions, stoichiometry, etc. of mixtures of particular that are fluorescently labeled with differently colored fluorophores having different excitation/emission spectra using fluctuation microscopy.Type: ApplicationFiled: January 11, 2019Publication date: November 5, 2020Applicants: Universiteit Hasselt, Ludwig-Maximilians-Universität MünchenInventors: Jelle Hendrix, Nick Smisdom, Don Lamb, Waldemar Schrimpf
-
Publication number: 20200337279Abstract: This disclosure provides new animal models for studying Usher syndrome and developing new therapy. The technology is implemented in pigs, and other large animals in which the ophthalmic architecture and function more closely resembles architecture and function of the human eye. The animals have a genetic modification in which all or a portion of a human gene known to cause Usher syndrome in human patients replaces the host gene. Animals can be cloned or bred to be homozygous at the targeted locus, whereupon they manifest symptoms and signs of Usher syndrome. Since a substantial portion of the targeted gene has been humanized, the animals can be used to develop and test pharmacological agents such as gene therapy that are sequence dependent.Type: ApplicationFiled: April 27, 2020Publication date: October 29, 2020Applicants: Molecular Cell Biology, Ludwig-Maximilians-Universität München (LMU)Inventors: Uwe Wolfrum, Kerstin Nagel-Wolfrum, Nikolai Klymiuk, Eckhard Wolf
-
Patent number: 10745437Abstract: The present invention provides means and methods for equipping a polypeptide of interest at its C-terminus with a versatile adaptor amino acid that allows the functionalization of the polypeptide of interest.Type: GrantFiled: December 19, 2018Date of Patent: August 18, 2020Assignees: LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN, FORSCHUNGSVERBUND BERLIN E.V.Inventors: Heinrich Leonhardt, Jonas Helma, Dominik Schumacher, Christian Hackenberger